Molecular drug design, theoretical, experimental approaches and new framework of novel oxazol dihydroquinoxaline (ODQ): Efficient synthesis, crystallographic, computational investigation, DFT calculation, ADME analysis and antiangiogenic molecular docking

Abstract

Drug design, also known as rational drug design, is a methodical procedure that seeks to discover and develop novel chemicals with therapeutic potential. The process entails the identification and modification of molecular structures that can efficiently interact with biological targets in order to achieve a desired therapeutic effect. The title compound, 1-([3-(4-chlorophenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl)-3-phenyl-1,2-dihydroquinoxalin-2-one ODQ (c), was synthesized with good yield by adding the solution of 1-allyl-3-phenylquinoxalin-2(1H)-one and 4-chlorobenzaldehyde oxime in dichloromethane. This mixture was then mixed with an excess of aqueous sodium hypochlorite solution while stirring at 0–5 °C. The resulting mixture was dried to obtain a crude product. The structure of the compound was confirmed by NMR and LC-MS spectra. The single-crystal X-ray studies conform to the 3D structure of the molecule. The molecule crystallizes in the triclinic system with the space group P-1. Hirshfeld surface analysis confirms the intermolecular interactions of the type CH…O and CH…N contacts. DFT calculations were performed to determine the electronic properties of the molecule. MEP analysis predicts the chemical reactive sites around oxygen and nitrogen atoms. This investigation has provided valuable insights that could drive significant advancements in molecular science and drug design. Additionally, the molecular docking studies elucidated the compound's interactions with various biological targets. The notable binding affinities observed for these targets highlight the potential therapeutic relevance of the synthesized compound across a range of disease conditions.